To treatment, even among patients treated during the acute phase [4]. Since

To treatment, even among patients treated during the acute phase [4]. Since 1996, there has been an increasing incidence of orally transmitted Chagas disease outbreaks in Amazon region. It is possible to quickly treat patients who are diagnosed during the acute phase of the disease and accompanied by regular monitoring of treatments [5,6,7,8,9]. Descriptive follow-up studies of patients treated with Chagas disease hope to identify mediate healing to detect early clinical and/or serological markers of the progression to chronic diseaseClinical Follow-Up of Acute Chagas Diseaseand to establish criteria for earlier indication of retreatment, since the potential of chronicity is smaller than more precocious is the attempt to treat. So, the objective of this study is to describe clinical, serological and parasitological response to treatment with benznidazol in a short and in a medium period of time of persons with acute Chagas disease from Amazon region.Methods Ethics StatementThe protocol of this work was submitted and approved by the Research Ethical Committee of Evandro Chagas Institute, Ananindeua, Para State, Autophagy Brazil. Protocol approval number: ?0004/2004. All subjects enrolled provided written informed consent, during 2004 (post acute phase to all of those included before 2004).incubation with sera, lyophilized fluorescein-conjugated antihuman IgG antibodies (Fluoline G BIOLAB) or fluoresceinconjugated anti-human IgM antibodies (Fluoline M BIOLAB) were added. Dilutions of 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640 and 1:1280 were used, and titers less than 1:40 were considered negative. The IHA technique was also used for the qualitative detection of IgG antibodies. To confirm serological clearance of antibodies, the first negative result was followed by two subsequent sample collections at Autophagy 90-day intervals with repetition of both assays. Individuals with three consecutive negative results by indirect IFA and IHA were considered serologically cured.Cardiac EvaluationTo evaluate disease progression in those who experienced an acute infection prior to 2002, we reanalyzed recovered electrocardiograms (ECG). We also reexamined existing echocardiograms from the same period. For a subsequent evaluation, patients underwent further electrocardiographic (classic 12-lead ECG) and echocardiographic examination at two reference centers for cardiology: the Luiz Decourt Foundation and Clinical Hospital ?Gaspar Viana Foundation. The analysis met the criteria stipulated by Brazilian Society of Cardiology [12].Patients and Study ProtocolThis is the first cohort study of Chagas disease realized with treated patients from Amazon region, mainly transmitted by oral route [10]. We included all persons identified in outpatient with acute Chagas disease confirmed by direct and indirect parasitological tests (blood smear or direct examination or Quantitative Buffy Coat QBC, blood culture and xenodiagnosis) and/or a serological test for the acute phase marker (IgM). Patients with infections acquired in Amazon region (Para and Amapa States), ??during the period from 1988 to 2005 who agreed to participate in follow-up monitoring were enrolled in the study. Those patients treated prior to 1998 were included based on records from the Chagas disease Laboratory at the Evandro Chagas Institute and were invited 1676428 to participate in study. A 20 ml blood sample was collected from patients who agreed to participate. Blood samples were used to survey peripheral T. cruzi hemo.To treatment, even among patients treated during the acute phase [4]. Since 1996, there has been an increasing incidence of orally transmitted Chagas disease outbreaks in Amazon region. It is possible to quickly treat patients who are diagnosed during the acute phase of the disease and accompanied by regular monitoring of treatments [5,6,7,8,9]. Descriptive follow-up studies of patients treated with Chagas disease hope to identify mediate healing to detect early clinical and/or serological markers of the progression to chronic diseaseClinical Follow-Up of Acute Chagas Diseaseand to establish criteria for earlier indication of retreatment, since the potential of chronicity is smaller than more precocious is the attempt to treat. So, the objective of this study is to describe clinical, serological and parasitological response to treatment with benznidazol in a short and in a medium period of time of persons with acute Chagas disease from Amazon region.Methods Ethics StatementThe protocol of this work was submitted and approved by the Research Ethical Committee of Evandro Chagas Institute, Ananindeua, Para State, Brazil. Protocol approval number: ?0004/2004. All subjects enrolled provided written informed consent, during 2004 (post acute phase to all of those included before 2004).incubation with sera, lyophilized fluorescein-conjugated antihuman IgG antibodies (Fluoline G BIOLAB) or fluoresceinconjugated anti-human IgM antibodies (Fluoline M BIOLAB) were added. Dilutions of 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640 and 1:1280 were used, and titers less than 1:40 were considered negative. The IHA technique was also used for the qualitative detection of IgG antibodies. To confirm serological clearance of antibodies, the first negative result was followed by two subsequent sample collections at 90-day intervals with repetition of both assays. Individuals with three consecutive negative results by indirect IFA and IHA were considered serologically cured.Cardiac EvaluationTo evaluate disease progression in those who experienced an acute infection prior to 2002, we reanalyzed recovered electrocardiograms (ECG). We also reexamined existing echocardiograms from the same period. For a subsequent evaluation, patients underwent further electrocardiographic (classic 12-lead ECG) and echocardiographic examination at two reference centers for cardiology: the Luiz Decourt Foundation and Clinical Hospital ?Gaspar Viana Foundation. The analysis met the criteria stipulated by Brazilian Society of Cardiology [12].Patients and Study ProtocolThis is the first cohort study of Chagas disease realized with treated patients from Amazon region, mainly transmitted by oral route [10]. We included all persons identified in outpatient with acute Chagas disease confirmed by direct and indirect parasitological tests (blood smear or direct examination or Quantitative Buffy Coat QBC, blood culture and xenodiagnosis) and/or a serological test for the acute phase marker (IgM). Patients with infections acquired in Amazon region (Para and Amapa States), ??during the period from 1988 to 2005 who agreed to participate in follow-up monitoring were enrolled in the study. Those patients treated prior to 1998 were included based on records from the Chagas disease Laboratory at the Evandro Chagas Institute and were invited 1676428 to participate in study. A 20 ml blood sample was collected from patients who agreed to participate. Blood samples were used to survey peripheral T. cruzi hemo.